central spasticity

November 11, 2016

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Abstract The global exposure of Sativex® (Δ9-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since it was…

July 4, 2012

A mechanism-based classification of pain in multiple sclerosis

Abstract Pharmacological treatment of pain in multiple sclerosis (MS) is challenging due to the many underlying pathophysiological mechanisms. Few controlled…

March 3, 2010

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids

Abstract Cannabinoids such as Cannabis-based medicinal extracts (CBMEs) are increasingly being used in the treatment of spasticity associated with multiple…

October 1, 2008

Cannabinoids in the management of spasticity associated with multiple sclerosis

Abstract The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies…